Nanoenabled intracellular zinc bursting for efficacious reversal of gefitinib resistance in lung cancer

Following the identification of specific epidermal growth factor receptor (EGFR)-activating mutations, gefitinib, one of the first-generation tyrosine kinase inhibitors (TKIs), has proven efficacious in targeting NSCLC that is driven by specific EGFR-activating mutations.However, most patients who initially respond to gefitinib, develop acquired resistance.In the current study, we devised a novel strategy to enhance the efficacy of gefitinib.We developed a simple and effective, nano-interrupter termed zeolitic imidazolate framework-8@Gefitinib@hyaluraonic nanoparticle (ZIF-8@G@HA NP).This nanoparticle was prepared by loading gefitinib onto a ZIF-8 nanoplatform followed by coating with hyaluronic acid (HA).The burst of Zn 2+ release triggered by pH-sensitive degradation of ZIF-8@G@HA NPs was shown to enhance the efficacy of gefitinib in parental lung carcinoma HCC827 cells and overcame acquired gefitinib resistance in gefitinib drug resistant (GDR) HCC827 cells.We found that when treated with ZIF-8@G@HA NPs, Zn 2+ acts synergistically with gefitinib via increased apoptosis in both parental and GDR HCC827 cells.Consistently, this in vitro activity was correlated with in vivo tumor growth inhibition.Interestingly, GDR cells were more sensitive to Zn 2+ when compared with parental cells.We further found that ZIF-8 NPs overcame gefitinib resistance by triggering reactive oxygen species (ROS) generation and consequent cell cycle arrest at the G2/M phase, resulting in cancer cell apoptosis.Zn 2+ was also found to block P-gp activity, facilitating the accumulation of gefitinib in GDR cells, thus enhancing the anti-tumor efficacy of gefitinib resulting in reversal of gefitinib resistance.Thus, this study offers a novel and promising strategy to surmount acquired gefitinib resistance via cell cycle arrest at the G2/M phase by facilitating gefitinib accumulation in GDR cells.